Kymera Therapeutics (NASDAQ:KYMR) Monday reported positive Phase 1 results from its healthy volunteer study of KT-621, a first-in-class oral STAT6 degrader, sending shares up +35% in premarket ...

About STAT6 Degrader STAT6 is a historically undrugged essential transcription factor in the IL-4/IL-13 signaling pathways and the central driver of T helper type 2 (TH2) inflammation in allergic ...

KT-621 has the potential to provide dupilumab-like activity with an oral small molecule profile for TH2 driven allergic and atopic disease KT-621 demonstrated strong degradation of STAT6 in human ...

STAT6 pathway activation is associated with poor prognosis in multiple cancers including hepatocellular carcinomas (HCC) and patients with high STAT6 activation may potentially benefit from exoASO ...

Goal is to develop an oral STAT6 degrader investigational new drug with potential to address the needs of patients with type 2 inflammation Nurix anticipates ...

Key takeaways: The STAT5 and STAT6 transcription factors activate Th9 cells. Th9 cells produce the IL-9 cytokine, which causes allergic inflammation. Th9 levels may indicate which patients may ...

STAT6 pathway activation is associated with poor prognosis in multiple cancers including hepatocellular carcinomas (HCC) and patients with high STAT6 activation may potentially benefit from exoASO ...

"By partnering with LEO Pharma, we hope to explore the potential of the STAT6 pathway to bring forward an oral option for patients suffering from chronic inflammatory conditions," said Flavius ...

The pathway to which STAT6 belongs is highly targeted by asthma biologics, with each drug targeting a single molecule within the T2 inflammatory response.

In allergic diseases, STAT6 is a critical transcription factor in the IL-4 and IL-13 signaling pathways and the key driver of Th2 inflammation. Because STAT6 functions through protein-protein and ...